In contrast, a recent study found that prostate tumors with PTEN loss exhibited strong activation of both innate and adaptive immune systems, with increased interferon-gamma response genes and CD8+ lymphocytes, suggesting they may respond better to immunotherapies [23]. The gene discussed is PTEN; the disease is prostate neoplasm.